Adding pharmacogenetics information to drug labels: Lessons learned

Pharmacogenetics and Genomics

Volumn 16, Issue 12, 2006, Pages 847-854

  Haga, Susanne B ^a   Thummel, Kenneth E ^b   Burke, Wylie ^b  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

6 mercaptopurine; Cancer; Clinical utility; Drug labels; FDA; Irinotecan; TPMT; UGT1A1

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; 6 THIOINOSINE MONOPHOSPHATE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; AZATHIOPRINE; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; COLORECTAL CANCER; CROHN DISEASE; CYTOTOXICITY; DIARRHEA; DRUG LABELING; ENTERITIS; EXPERIENCE; GENETIC VARIABILITY; HUMAN; METASTASIS; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; SHORT SURVEY;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DRUG LABELING; GLUCURONOSYLTRANSFERASE; HUMANS; METHYLTRANSFERASES; PHARMACOGENETICS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VARIATION (GENETICS);

EID: 33751103939     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/01.fpc.0000236322.88433.ac     Document Type: Short Survey

References (57)

1. Krynetski EY, Tai HL, Yates CR, Fessing MY, Loennechen T, Schuetz JD, et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996; 6:279-290.
2. Coulthard S, Hogarth L. The thiopurines: an update. Investig N Drugs 2005; 23:523-532.
3. Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85:323-333.
4. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32:651-662.
5. Honchel R, Aksoy IA, Szumlanski C, Wood TC, Otterness DM, Wieben ED, et al. Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol 1993; 43:878-887.
6. Krynetski EY, Schuetz JD, Galpin AJ, Pui CH, Relling MV, Evans WE. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995; 92:949-953.
7. Tai HL, Krynetski EY, Yates CR, Loennechen T, Fessing MY, Krynetskaia NF, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet 1996; 58:694-702.
8. Szumlanski C, Otterness D, Her C, Lee D, Brandriff B, Kelsell D, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17-30.
9. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26:186-191.
10. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989; 46:149-154.
11. Lennard L, Lilleyman JS, Van Loon JA, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336:225-229.
12. Evans WE, Homer MH, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr 1991; 119:985-989.
13. McLeod HL, Coulthard S, Thomas AE, Pritchard SC, King DJ, Richards SM, et al. Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999; 105:696-700.
14. Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
15. Relling MV, Hancock ML, Boyett JM, Pui C-H, Evans WE. Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 1999; 93:2817-2823.
16. Shitara T, Shimada A, Hanada R, Matsunaga T, Kawa K, Mugishima H, et al. Irinotecan for children with relapsed solid tumors. Pediatr Hematol Oncol 2006; 23:103-110.
17. Baek JH, Kim JG, Jeon SB, Chae YS, Kim DH, Sohn SK, et al. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer. Br J Cancer 2006; 94:1407-1411.
18. Marsh S, McLeod HM. Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 2004; 5:835-843.
19. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11): role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101:847-854.
20. Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 2006; 20:163-175.
21. Hall D, Ybazeta G, Destro-Bisel G, Petzl-Erler ML, Di Renzo A. Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates. Pharmacogenetics 1999; 9:591-599.
22. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347:578-581.
23. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60:6921-6926.
24. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22:1382-1388.
25. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10:5151-5159.
26. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91:678-682.
27. Code of Federal Regulations. Title 21: food and drugs, Part 201 - labeling, subpart B - labeling requirements for prescription drugs and/or insulin 57, Section 201.57, specific requirements on content and format of labeling for human prescription drugs.
28. Food and Drug Administration, Center for Drug Evaluation and Research. Transcript of the clinical pharmacology subcommittee of the Advisory Committee of Pharmaceutical Science. November 11, 2004. Available at: http://www.fda.gov/ ohrms/dockets/ac/04/transcripts/2004-4079T1.htm. [Accessed 17 December 2004].
29. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95:8170-8174.
30. Ando M, Hasegawa Y, Ando Y. Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan. Investig N Drugs 2005; 23:539-545.
31. Food and Drug Administration. Revised label for Purinethol, July 15, 2004. Available at: http://www.fda/gov/medwatch/SAFETY/2004/04Jul_labels/ Purinethol_PI.pdf. [Accessed 24 February 2005].
32. Food and Drug Administration. Revised label for Camptosar, July 21, 2005. Available at http://www.fda.gov/cder/foi/label/2005/020571s024,027,028lbl.pdf. [Accessed 3 August 2005].
33. Smits KM, Schouten JS, Smits LJ, Stelma FF, Nelemans P, Prins MH. A review on the design and reporting of studies on drug-gene interactions. J Clin Epidemiol 2005; 58:651-654.
34. Pfizer. Background document on the UGT1A1 Polymorphisms and irinotecan toxicity: ACPS November 3, 2004 Advisory Committee Meeting (Amended). Available at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4079B1_08_Pfizer-UGT1A1- Addendum.pdf. [Accessed 22 November 2004].
35. Fruend CL, Clayton EW, Wilfond BS. Natural setting trials: improving the introduction of clinical genetic tests. J Law Med Ethics 2004; 32:106-110.
36. Kees van Grootheest AC, Edwards IR. Labelling and 'Dear Doctor' letters: are they noncommittal? Drug Saf 2002; 25:1051-1055.
37. Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D, et al. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12:295-301.
38. Feldman HL. Pushing drugs: genomics and genetics, the pharmaceutical industry, and the law of negligence. Washburn Law J 2003; 42:575-599.
39. Howlett MJ, Avard D, Knoppers BM. Physicians and genetic malpractice. Med Law 2002; 21:661-680.
40. Rothstein MA, Hoffman S. Genetic testing, genetic medicine, and managed care. Wake Forest Law Rev 1999; 34:849-888.
41. FDA News. FDA clears genetic test that advances personalized medicine test helps determine safety of drug therapy. Available at http://www.fda.gov/ bbs/topics/NEWS/2005/NEW01220.html (Accessed 22 August 2005).
42. Phillips KA, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics 2004; 5:1139-1149.
43. Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics 2006; 16:139-147.
44. Almarsdottir AB, Bjornsdottir I, Traulsen JM. A lay prescription for tailor-made drugs: focus group reflections on pharmacogenomics. Health Policy 2005; 71:233-241.
45. The Royal Society. Pharmacogenetics dialogue. Available at http://www.royalsoc.ac.uk/downloaddoc.asp?id = 2120. [Accessed 20 January 2006].
46. Bevan JL, Lynch JA, Dubriwny TN, Harris TM, Achter PJ, Reeder AL, Condit CM, et al. Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med 2003; 5:393-399.
47. Hayflick AFJ, Eiff MP, Carpentar L, Steinberger J. Primary care physicians' utilization and perceptions of genetics services. Genet Med 1998; 1:13-18.
48. Metcalfe S, Hurworth R, Newstead J, Robins R. Needs assessment study of genetics education for general practitioners in Australia. Genet Med 2002; 4:71-77.
49. Food and Drug Administration. Guidance document: pharmacogenomic data submissions (March 2005). Available at http://www.fda.gov/cder/guidance/6400fnl. pdf. [Accessed 23 March 2005].
50. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I35 9L mutant forms. Arch Biochem Biophys 1996; 333:447-458.
51. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427:537-541.
52. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427:541-544.
53. Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF, et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 1997; 7:361-367.
54. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353:717-719.
55. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285-2293.
56. Relling MV, Pui C-H, Cheng C, Evans WE. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107:843-844.
57. Stanulla M, Schaeffeler E, Flohr T, Cario G, Schrauder A, Zimmermann M, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 2005; 293:1485-1489.